Fluorescent conjugates targeting FRα are employed in late-stage clinical studies and have demonstrated favourable contrast for ovarian cancer FIGS, leading to improved surgical outcome [8, 40, 41]. Here, FOLR1 is linked to ovarian carcinoma.